The degeneration of striatal MSNs is a cardinal pathology in Huntington’s disease and there are several lines of preclinical evidence suggesting that PDE10A inhibition may ameliorate this degenerative process [63,64]. This evidence concerns the gene PDE10A and juvenile Huntington disease.